Abstract:Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA), circulating tumor DNA (ctDNA), and circulating tumor cells (CTCs) can be isolated from the blood and other body fluids. This review will focus on current technologies and clinical applications for liquid biopsies. ctDNA/cfDNA has been isolated and analyzed using many techniques, e.g., droplet digital polymerase chain reaction, beads, emulsion, amplification, and magnetics (BEAMing), tagged-amplicon deep sequencing (TAm-Seq), cancer personalized profiling by deep sequencing (CAPP-Seq), whole genome bisulfite sequencing (WGBS-Seq), whole exome sequencing (WES), and whole genome sequencing (WGS). CTCs have been isolated using biomarker-based cell capture, and positive or negative enrichment based on biophysical and other properties. ctDNA/cfDNA and CTCs are being exploited in a variety of clinical applications: differentiating unique immune checkpoint blockade response patterns using serial samples; predicting immune checkpoint blockade response based on baseline liquid biopsy characteristics; predicting response and resistance to targeted therapy and chemotherapy as well as immunotherapy, including CAR-T cells, based on serial sampling; assessing shed DNA from multiple metastatic sites; assessing potentially actionable alterations; analyzing prognosis and tumor burden, including after surgery; interrogating difficult-to biopsy tumors; and detecting cancer at early stages. The latter can be limited by the small amounts of tumor-derived components shed into the circulation; furthermore, cfDNA assessment in all cancers can be confounded by clonal hematopoeisis of indeterminate potential, especially in the elderly. CTCs can be technically more difficult to isolate that cfDNA, but permit functional assays, as well as evaluation of CTC-derived DNA, RNA and proteins, including single-cell analysis. Blood biopsies are less invasive than tissue biopsies and hence amenable to serial collection, which can provide critical molecular information in real time. In conclusion, liquid biopsy is a powerful tool, and remarkable advances in this technology have impacted multiple aspects of precision oncology, from early diagnosis to management of refractory metastatic disease. Future research may focus on fluids beyond blood, such as ascites, effusions, urine, and cerebrospinal fluid, as well as methylation patterns and elements such as exosomes.

Liquid biopsy using non-coding RNAs and extracellular vesicles for breast cancer management

Prospects for liquid biopsy using microRNA and extracellular vesicles in breast cancer

The functional and clinical roles of liquid biopsy in patient-derived models

Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer

Liquid biopsy: paving a new avenue for cancer research

Liquid biopsy: current technology and clinical applications

Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer

Liquid biopsy in breast cancer: A comprehensive review

Liquid biopsy for breast cancer and other solid tumors: a review of recent advances

Liquid Biopsy in the Clinical Management of Cancers

Exosomes as a new frontier of cancer liquid biopsy

Exosome-based liquid biopsies in cancer: opportunities and challenges

Exosomal ncRNAs in liquid biopsies for lung cancer

Liquid Biopsies, Novel Approaches and Future Directions

Liquid Biopsy for the Management of Patients with Colorectal Cancer

Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer

LIQUID BIOPSY: A NON-INVASIVE TOOL TO DETECT CANCER AT AN EARLY STAGE

Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments

Extracellular Vesicles for Childhood Cancer Liquid Biopsy

Early Detection, Precision Treatment, Recurrence Monitoring: Liquid Biopsy Transforms Colorectal Cancer Therapy

[Current situation and prospect of breast cancer liquid biopsy].